FindTrial
Sign In

Pegylated G-CSF

DRUG5 trials

Sponsors

AstraZeneca, Alliance for Clinical Trials in Oncology, Washington University School of Medicine, Ospedale San Raffaele, Australasian Gastro-Intestinal Trials Group

Conditions

Childhood TeratomaChoriocarcinomaDiabetes Mellitus, Type 1Extragonadal SeminomaGerm Cell TumorGerminomaLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVMalignant Germ Cell Neoplasm

Phase 2

Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma
TerminatedNCT02469116
Washington University School of MedicineOvarian Cancer
Start: 2006-01-31End: 2010-03-31Updated: 2016-08-19
Minimal Islet Transplant at Diabetes Onset
CompletedNCT02505893
Ospedale San RaffaeleDiabetes Mellitus, Type 1
Start: 2015-04-30End: 2023-12-31Updated: 2024-02-22
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
Active, not recruitingNCT06094140
Australasian Gastro-Intestinal Trials GroupPancreatic Cancer
Start: 2022-05-20End: 2026-06-01Updated: 2026-05-06

Phase 3

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Active, not recruitingNCT01933932
AstraZenecaLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Start: 2013-09-25End: 2026-12-31Updated: 2026-07-21
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Active, not recruitingNCT02375204
Alliance for Clinical Trials in OncologyChildhood Teratoma, Choriocarcinoma, Extragonadal Seminoma +8
Start: 2015-08-06End: 2031-06-01Updated: 2026-06-16

Related Papers

Induction of immune education in type 1 diabetes through controlled allogeneic islet rejection at onset: a monocentric open-label pilot study.
2025-12-04
Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease
Journal of Clinical Oncology2024-07-1911 citations
High-Dose Chemotherapy in Relapsed or Refractory Metastatic Germ-Cell Cancer: The Scotland Experience.
2018-11-174 citations
Abstract 4760: Joint modeling of longitudinal tumor dynamics and survival in non-small cell lung cancer (NSCLC) patients
Cancer Research2018-07-018 citations
A Closer Look at the Management of Advanced Testicular Cancer
Oncology Times2018-04-24
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
2017-08-2419 citations
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With <i>KRAS</i>-Mutant Advanced Non–Small Cell Lung Cancer
JAMA2017-05-09330 citations
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
BMC Cancer2017-03-0620 citations
Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1).
2015-12-3026 citations
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.
2015-06-3059 citations